GLP-One Drugs: Surging Demand & Expanding Uses

Global demand for GLP-One weight loss drugs is projected to skyrocket in 2026, driven by pill versions, price reductions, Medicare/Medicaid coverage, and expanded uses beyond obesity and diabetes. Lilly and Novo Nordisks pill versions will be more affordable and accessible, with potential uses in heart attacks, sleep apnea, kidney/liver diseases, uterine fibroids, colon cancer, menopause symptoms, and addictive behaviors. Despite setbacks in Alzheimers trials, overall demand remains high, with Lillys tirzepatide becoming the worlds best-selling prescription medicine. The market is vast, with nearly 40% of U.S. adults obese, and one in five U.S. adults trying or currently using GLP-One drugs.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.